Loading
Life sciences · Phase EARLY_PHASE1 Trial
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase EARLY_PHASE1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04846829). This is a study registration, not published results. Lead sponsor: University of California, Los Angeles. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: EARLY_PHASE1. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Major Depressive Disorder. Interventions: DRUG: Placebo; DEVICE: intermittent theta burst stimulation; DRUG: intravenous citalopram hydrochloride (CIT); DEVICE: continuous theta burst stimulation. Primary outcome measures: Percent change in Hamilton Depression Scale , through study completion, an average of 10 days. Brief summary: This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quantitative electroencephalography (qEEG) brain activity recordings, and mood surveys. Study activities will be performed over the course of 4 weeks.